Compare Abbott Laboratories (ABT) vs Chart Industries Inc (GTLS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Chart Industries Inc — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Chart Industries Inc trades at $209.36 (market cap $10.02B). The key difference: Abbott Laboratories is far larger — about 16.7× Chart Industries Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Chart Industries Inc pays none. Which is the better fit depends on your goals.
| ABT | GTLS | |
|---|---|---|
Market Cap | $166.94B | $10.02B |
Sector | Health | Technology |
52-Week High | $136.62 | $209.29 |
52-Week Low | $82.57 | $164.90 |
Enterprise Value | $193.69B | $13.54B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
GTLS trades at $208.73 with minimal daily movement, showing technical bullish signals from moving averages while oscillators remain neutral. The company reported $4.26B revenue for 2025 but has missed earnings expectations for three consecutive quarters, with negative profit margins and elevated valuation ratios. Recent news highlights Baker Hughes' pending $13.6B acquisition and new supply agreements supporting future growth.
Investment outlook remains mixed with strong analyst buy consensus (54%) offset by recent earnings underperformance. Key opportunities include acquisition premium potential and operational scale, while risks center on profitability challenges and integration execution. The stock's valuation appears stretched given current negative returns on equity and assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Chart Industries Inc
Chart Industries is a leading manufacturer of highly engineered cryogenic equipment. Its products are used throughout the liquid gas supply chain, including clean energy applications like hydrogen and LNG.
Read more on GTLS →
